![if gte IE 9]> <![endif]>
Cerdelga is the ONLY first-line oral therapy for most adults with Gaucher disease type 1, indicated for the long-term treatment of both naive and switch patients.1,2
Cerdelga is indicated for the long-term treatment of most adult patients with Gaucher disease type 1.1 Cerdelga, a substrate reduction therapy (SRT), works by reducing the amount of GL-1 produced, allowing the cells’ residual enzyme activity to break down the substrate.1,4
The safety and efficacy of Cerdelga have been demonstrated in clinical trials for both Naive (ENGAGE and Phase 2) and Switch (ENCORE) Patients.1,4,5
A Cerdelga Patient’s Treatment Journey
Hear from Shauna—a real Cerdelga patient—as she shares her experience of living with Gaucher disease type 1 and how, with the help of her health care team, she wasable to switch from an ERT to Cerdelga.